Wave Life Sciences has initiated the Phase 2a portion of its INLIGHT™ trial to test WVE-007, an investigational RNA medicine targeting obesity and related cardiometabolic diseases. Earlier Phase 1 results showed that a single dose of WVE-007 significantly reduced visceral fat by 14% and total fat by 5% while preserving muscle, with potential for once or twice-yearly dosing. The Phase 2a trial will enroll individuals with higher BMI and include assessments of body composition, weight loss, and metabolic health markers over 12 months. This trial aims to further validate WVE-007's potential to improve obesity treatment and reduce risks for type 2 diabetes and cardiovascular disease, with additional Phase 2 trials planned for later in 2026.
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
LithiumBank Resources Corp. has appointed Logan R. Harris as Vice President of Project Development to lead the advancement of its Boardwalk Lithium Brine Project in Alberta. Harris brings over 15 years of experience in engineering and project develop...
